Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
- Registration Number
- NCT01462708
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Brief Summary
The purpose of this study is to assess MK-9470 Positron Emission Tomography (PET) imaging as a tool to evaluate the activity of the CB-1 receptor in the brain.
- Detailed Description
The underlying goal of this study is to assess MK-9470 PET imaging as a tool to evaluate the activity of the CB-1 receptor in the brain of Parkinson's Disease (PD) research participants.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Assess [18F]MK-9470 and PET imaging [18F]MK-9470 To Assess \[18F\]MK-9470 and PET imaging
- Primary Outcome Measures
Name Time Method Dynamic uptake and washout of [18F]MK-9470 Approximately 2 years To assess the dynamic uptake and washout of \[18F\]-MK-9470 in brain using positron emission tomography (PET) in early Parkinson disease and advanced Parkinson disease with and without dyskinesia and similarly aged healthy control subjects as a potential imaging biomarker of the cannabionoid-1 (CB-1) receptor in brain.
- Secondary Outcome Measures
Name Time Method To acquire safety data Approximately 2 years Safety will be assessed by the number of adverse events experienced by subjects and any clinically significant changes in laboratory tests or vital signs.
Trial Locations
- Locations (1)
Institute for Neurodegenerative Disorders
🇺🇸New Haven, Connecticut, United States